Released on 10/01/13

AS its 12-year-old biomedical and pharmaceutical scene matures, Singapore is beginning to change the way in which it adds value to some of the largest companies it has wooed here.

Bayer HealthCare said said it is consolidating six separate cancer-related research tie-ups with Singapore researchers and clinician under a single Integrated Translational Oncology Network geared towards addressing the growing cancer burden in Asia.

Bayer's network, which was facilitated by the Singapore Economic Development Board (EDB), will hopefully accelerate the typical 15-year, US$1 billion process taken to translate research done at the bench to the patient's bedside.

It counts the Cancer Science Institute of Singapore at the National University of Singapore, the National Cancer Centre Singapore, Singapore General Hospital, A*Star's Singapore Bioimaging Consortium and the Duke-NUS Graduate Medical School Singapore, as some of its partners.

Source Business Times